No Benefit Offered By Bevacizumab For Newly Diagnosed Glioblastoma
Jun 4, 2013 | Posted by: roboblogger | Full story: MediLexicon
The angiogenesis inhibitor bevacizumab failed to increase overall survival or statistically significant progression-free survival for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.
Since: Dec 05
Avastin fails to prolong life in glioblastoma brain cancer patients?
Wow! This is blockbuster news! In one study, patients who were expected to benefit the most from Avastin based on "genetic" testing had the worst survival rates.
Bevacizumab-induced tumor calcifications can be elicited in glioblastoma microspheroid culture and represent massive calcium accumulation death (MCAD) of tumor endothelial cells
Since: Dec 05
MCED explains why glioblastoma (the most common primary brain tumor) patients who have favorable responses to bevacizumab (Avastin) develop early calcifications in the tumor bed while glioblastoma patients with poor responses to bevacizumab do not develop calcifications.”
|TV anchor Estela Casas to discuss experience wi... (Sep '10)||Jul 16||SJM||42|
|Breast Cancer Study||Jul 16||Texan||6|
|Reno couple accuses Renown of deceptive practices (Dec '13)||Jul 14||liberation theology||12|
|Doctor group urges against gynecological pelvic...||Jul 1||pailrider||3|
|Go-slow approach can work for some prostate-can... (May '08)||Jun 23||Burke||18|
|Gene expression profiling test expands to asses...||Jun '14||Sandy||1|
|African American Women With Breast Cancer Less ...||Jun '14||This is sad||1|